Cell Sheet based Gene Therapy Market Forecast with Size and Share Analysis 2025 to 2034
Global Cell Sheet-based Gene Therapy Market Size is valued at US$ 719.9 Mn in 2024 and is predicted to reach US$ 2,405.4 Bn by the year 2034 at an 13.1% CAGR during the forecast period for 2025 to 2034.
Cell Sheet-based Gene Therapy Market Size, Share & Trends Analysis Distribution by Cell-Sheet Type (Monolayer Cell-sheet Type, Co-culture Cell-sheet Type, Multilayered Cell-sheet Type), Source Type (Allogenic, Autologous, and Stem-cell Derived), Technology (Cell sheet-based Engineering Techniques and Gene Delivery Methods [CRISPR/Cas9, Viral Vector-Based, Non-Viral Vector-Based]), Application (Oncology, Cardiology, Genetic Disorders, Ophthalmology), End-user (Hospitals and Clinics, Biotech and Pharma Companies, Research and Academic Institutions), and Segment Forecasts, 2025 to 2034
Cell sheet-based gene therapy is an advanced regenerative approach that combines gene therapy with tissue engineering. In this method, cells are genetically modified ex vivo and cultured into intact sheets on temperature-responsive surfaces. These sheets preserve the extracellular matrix and cell-to-cell connections, allowing them to be transplanted directly onto damaged tissues or organs. This technique improves cell survival, engraftment, and therapeutic protein delivery, making it promising for applications such as heart repair, corneal regeneration, skin healing, and periodontal therapy.
Global frameworks that have advanced the clinical and regulatory trajectory of these medicines, such as the FDA's RMAT designation, the EMA's ATMP pathway, and Japan's conditional approval approach, further fuel the growth of the cell sheet-based gene therapy market. Additionally, the market is witnessing technological convergence as a result of advancements in cryopreservation methods, gene editing integration, and temperature-responsive polymers, which enable more reliable and scalable product delivery. Despite this momentum, challenges remain, including fragmented late-stage clinical data, high manufacturing costs, and unclear reimbursement. However, these obstacles are being gradually addressed through cross-sector collaborations, positive real-world results, and increasing payer trust.
Competitive Landscape
Some of the Key Players in the Cell Sheet-based Gene Therapy Market:
- Abeona Therapeutics Inc.
- Emmaus Medical, Inc
- CellSeed Inc.
- Fujifilm Cellular Dynamics, Inc. (FCDI) (FUJIFILM Holdings Corporation)
- Japan Tissue Engineering Co., Ltd.
- Foundation ENEA Tech Biomedical
Market Segmentation:
The cell sheet-based gene therapy market is segmented by cell-sheet type, source type, technology, application, and end-user. By cell-sheet type, the market is segmented into monolayer cell-sheet type, co-culture cell-sheet type, multilayered cell-sheet type, and others. By source type, the market is segmented into allogenic, autologous, and stem-cell derived. By technology, the market is segmented into cell sheet-based engineering techniques [scaffold-free techniques, light-induced cell sheet technology, layer-by-layer assembly, temperature-responsive culture surfaces, others] and gene delivery methods [crispr/cas9, viral vector-based (e.g., lentivirus, adenovirus), non-viral vector-based (e.g., liposomes, nanoparticles), others]. By application, the market is segmented into oncology, cardiology, genetic disorders, ophthalmology, and others. By end-user, the market is segmented into hospitals and clinics, biotech and pharma companies, research and academic institutions, others.
By Cell-Sheet Type, the Monolayer Cell-Sheet Type Segment is Expected to Drive the Cell Sheet-based Gene Therapy Market
In 2024, the Monolayer Cell-sheet Type segment dominated the global market for cell sheet-based gene therapy. Due to its easier manufacturing method, intact cell-cell connections, and suitability for early-stage regenerative applications, monolayer cell sheets are expected to continue to dominate. While continuous clinical developments continue to broaden their therapeutic potential across a range of indications, their extensive use in skin, ocular, and mucosal therapies sustains steady demand.
The Oncology Segment by Application is Growing at the Highest Rate in the Cell Sheet-based Gene Therapy Market
The oncology segment leads the global market for cell sheet-based gene therapy. Due to the increasing demand for innovative, targeted delivery and tissue regeneration techniques, oncology is expected to maintain its market-leading position. Through scaffold-free, biocompatible platforms, cell sheet therapies improve therapeutic results and facilitate repair after resection, demonstrating tremendous potential in solid tumour therapy.
Regionally, North America Led the Cell Sheet-based Gene Therapy Market
The market for cell sheet-based gene therapy is expanding significantly in North America, largely because of the region's advanced healthcare system, high concentration of biotechnology and gene therapy companies, and substantial investment in regenerative medicine research. The United States is now the industry leader due to the presence of large companies, favourable regulatory environments, and expanding clinical research focused on cell sheet engineering for diseases of the skin, eyes, and heart.
The Asia-Pacific market for cell sheet-based gene therapy is expected to increase rapidly over the next five years as a result of Japan's strict regulations, increasing clinical activity, and strong collaboration between academia and industry. Advanced frameworks for regenerative medicine that help the region include Japan's Act on the Safety of Regenerative Medicine and the PMDA's fast-track approval processes. Furthermore, academic collaborations and public-private initiatives are supporting translational research, and greater infrastructure and biomanufacturing investment is anticipated to facilitate wider commercialization and accessibility.
Recent Developments:
- May 2025: The autologous cultured cartilage product JACC, developed by Japan Tissue Engineering Co., Ltd. (J-TEC), has been approved by the regulatory body to treat osteoarthritis in the knee, expanding its orthopaedic uses beyond its original indications.
- December 2024: J-TEC and VCCT Inc. formed a business and financial partnership to work together on the development of cell sheet engineering-based retinal regeneration treatments obtained from iPS cells. By assisting with preclinical research and pipeline expansion, VCCT will strengthen both businesses' standing in the ocular regenerative sector.
Cell Sheet-based Gene Therapy Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 719.9 Mn |
| Revenue Forecast In 2034 | USD 2,405.4 Mn |
| Growth Rate CAGR | CAGR of 13.1% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Cell-Sheet Type, By Source Type, By Technology, By Application, By End-user |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Argentina; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa |
| Competitive Landscape | Abeona Therapeutics Inc., Emmaus Medical, Inc, CellSeed Inc., Fujifilm Cellular Dynamics, Inc. (FCDI) (FUJIFILM Holdings Corporation), Japan Tissue Engineering Co. Ltd., and Foundation ENEA Tech Biomedical |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Cell Sheet-based Gene Therapy Market -
Cell Sheet-based Gene Therapy Market by Cell-Sheet Type-
- Monolayer Cell-sheet Type
- Co-culture Cell-sheet Type
- Multilayered Cell-sheet Type
- Others
Cell Sheet-based Gene Therapy Market by Source Type -
- Allogenic
- Autologous
- Stem-cell Derived
Cell Sheet-based Gene Therapy Market by Technology-
- Cell sheet-based Engineering Techniques
- Scaffold-Free Techniques
- Light-induced cell sheet technology
- Layer-by-Layer Assembly
- Temperature-Responsive Culture Surfaces
- Others
- Gene Delivery Methods
- CRISPR/Cas9
- Viral Vector-Based (e.g., Lentivirus, Adenovirus)
- Non-Viral Vector-Based (e.g., Liposomes, Nanoparticles)
- Others
Cell Sheet-based Gene Therapy Market by Application-
- Oncology
- Cardiology
- Genetic Disorders
- Ophthalmology
- Others
Cell Sheet-based Gene Therapy Market by End-user-
- Hospitals and Clinics
- Biotech and Pharma Companies
- Research and Academic Institutions
- Others
Cell Sheet-based Gene Therapy Market by Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cell Sheet-based Gene Therapy Market Size is valued at US$ 719.9 Mn in 2024 and is predicted to reach US$ 2,405.4 Bn by the year 2034
Cell Sheet-based Gene Therapy Market is expected to grow at a 13.1% CAGR during the forecast period for 2025 to 2034.
Abeona Therapeutics Inc., Emmaus Medical, Inc, CellSeed Inc., Fujifilm Cellular Dynamics, Inc. (FCDI) (FUJIFILM Holdings Corporation), Japan Tissue En
Cell-Sheet Type, Source Type, Technology, Application, and End-user are the key segments of the Cell Sheet-based Gene Therapy Market.
North America region is leading the Cell Sheet-based Gene Therapy Market.